ERBB2 and breast cancer: In a phase II trial, 69 HER2+ BC patients were subjected to NAT involving docetaxel, carboplatin, trastuzumab, and pyrotinib (TCbHy), resulting in a pCR rate of 55.1% (Liu Z. et al., 2022).